Nurse Practitioner · Miami, FL
NPI
1053357780
Since 2006
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
8950 N Kendall Dr, Suite 601
Miami, FL, 33176
Phone (305) 279-4500
Groups this clinician bills Medicare through
Medicare paid, 2023
$1,399
18 services
Medicare patients, 2023
16
Average age 81
Drug cost, 2024
$456K
123 prescriptions
Company payments, 2025
$1,371
From 15 companies
Medicare prescription drug claims, 2024
In 2024, the drug Sandra Valencia prescribed most often to Medicare patients was Dextrose In Water (Dextrose 5 % In Water), with 33 prescriptions and refills. In total Sandra Valencia wrote 123 Medicare prescriptions that cost $456K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-05-02.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Dextrose In Water Dextrose 5 % In Water | 33 | 33 | Under 11 | $123 |
| Milrinone Lactate Generic | 21 | 21 | Under 11 | $3,283 |
| Vyndamax Tafamidis | 20 | 20 | Under 11 | $434K |
Brand drugs: 69 claims; generic drugs: 54 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sandra Valencia $1,371 ($1,371 in general payments such as food, travel and fees) from 15 companies. The largest payer was Kestra Medical Technology Services, Inc. with $298.
| Company | Payments | Amount |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 4 | $298 |
| Cleerly, Inc. | 1 | $171 |
| Alnylam Pharmaceuticals Inc. ALNY | 2 | $149 |
| BridgeBio Pharma, Inc. BBIO | 6 | $137 |
| Medtronic, Inc. MDT | 1 | $101 |
| Pfizer Inc. PFE | 4 | $91.84 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $74.32 |
| Abbott Laboratories ABT | 3 | $69.97 |
| Merck Sharp & Dohme LLC MRK | 2 | $56.58 |
| Boston Scientific Corporation BSX | 2 | $53.27 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.